目的 分析天津市濱海新區(qū)漢沽中醫(yī)醫(yī)院門(mén)診降糖藥的使用情況及變化趨勢(shì),為臨床合理用藥提供參考。方法 采用回顧性分析方法,對(duì)2018-2021年天津市濱海新區(qū)漢沽中醫(yī)醫(yī)院門(mén)診降糖藥的銷(xiāo)售金額、用藥頻度(DDDs)、日均費(fèi)用(DDC)和排序比(B/A)等進(jìn)行統(tǒng)計(jì)分析。結(jié)果 2018-2021年,門(mén)診降糖藥的銷(xiāo)售金額和DDDs均呈逐年上升趨勢(shì)。其中胰島素類(lèi)降糖藥的銷(xiāo)售金額連續(xù)4年穩(wěn)居第1位?？诜?lèi)降糖藥中,α-糖苷酶抑制劑銷(xiāo)售金額2018、2019年居首位,2020、2021年二肽基肽酶4(DPP-4)抑制劑躍升至第1位。具體口服藥物中二甲雙胍的銷(xiāo)售金額和DDDs排序2018-2020年居首位,2021年利格列汀銷(xiāo)售金額迅速上升至第1位,達(dá)格列凈DDDs升至首位。除阿卡波糖、格列美脲、達(dá)格列凈、恩格列凈、二甲雙胍、維格列汀、瑞格列奈外,其余口服降糖藥各品種的DDC值均無(wú)明顯浮動(dòng)。注射類(lèi)降糖藥中,預(yù)混胰島素類(lèi)似物的DDDs排名連續(xù)4年始終位居第1位,其銷(xiāo)售金額2018-2020年也居首位,2021年降至第2位,長(zhǎng)效胰島素類(lèi)似物2018-2020年銷(xiāo)售金額居第2位,2021年升至第1位,且銷(xiāo)售金額逐年上升。除雙胰島素類(lèi)似物、度拉糖肽、利拉魯肽外,其余注射類(lèi)降糖藥的DDC值均基本穩(wěn)定。注射類(lèi)和口服類(lèi)降糖藥的B/A值均接近或等于1.00,說(shuō)明同步性良好。結(jié)論 天津市濱海新區(qū)漢沽中醫(yī)醫(yī)院門(mén)診降糖藥使用基本合理,新型口服降糖藥DPP-4抑制劑、SGLT2抑制劑使用量逐漸超過(guò)雙胍類(lèi)、α-糖苷酶抑制劑等傳統(tǒng)口服降糖藥。

Objective To analyze the use and change trend of hypoglycemic drugs in the outpatient department of Hangu Traditional Chinese Medicine Hospital in Tianjin Binhai New Area, so as to provide reference for clinical rational drug use. Methods The sales amount, DDDs, DDC and B /A of outpatient hypoglycemic drugs in Hangu Traditional Chinese Medicine Hospital in Tianjin Binhai New Area from 2018 to 2021 were statistically analyzed by retrospective analysis. Results From 2018 to 2021, the sales amount and DDDs of outpatient hypoglycemic drugs showed an upward trend year by year. Among them, the sales amount of insulin hypoglycemic drugs ranked first for four consecutive years. In oral hypoglycemic drugs, The sales amount of α-glycosidase inhibitors ranked first in 2018 and 2019, and DPP-4 inhibitors jumped to the first place in 2020 and 2021. Among the specific oral drugs, the sales amount and DDDs of metformin ranked first from 2018 to 2020, the sales amount of liggliptin rose rapidly to the first place in 2021, and the net DDDs of daggliptin rose to the first place. Except for acarbose, glimepiride, dalglitazin, engglitazin, metformin, vigliptin, and repaglinide, the DDC values of other oral hypoglycemic drugs did not fluctuate significantly. Among the injectable hypoglycemic drugs, the DDDs of premixed insulin analogues has always ranked first for four consecutive years, and its sales amount also ranked first from 2018 to 2020 and dropped to the second in 2021. The sales amount of long-acting insulin analogues ranked second from 2018 to 2020 and rose to the first in 2021, and the sales amount has increased year by year. The DDC values of other injectable hypoglycemic drugs were basically stable except for double insulin analogues, dulaglutide and liraglutide. The B/A values of injectable and oral hypoglycemic drugs are close to or equal to 1.00, indicating good synchronization. Conclusion The use of outpatient hypoglycemic drugs in Hangu Traditional Chinese Medicine Hospital in Tianjin Binhai New Area is basically reasonable. The use of new oral hypoglycemic drugs DPP-4 inhibitor and SGLT2 inhibitor gradually exceeds that of biguanidesα-glycosidase traditional oral hypoglycemic drugs such as glycosidase inhibitors.

R977